Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Wright Reports
|
$449.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Algeta ASA Opens Commercial Production Facility for Xofig
Algeta ASA announced that the Company has opened its commercial production facility for Xofig (radium Ra 223 dichloride) at the Institute for Energy Technology (IFE) in Kjeller, Norway. Xofigo is a particle-emitting radioactive therapeutic agent. It was approved by the US Food and Drug Administration (FDA) on May 15, 2013 for the treatment of patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral metastatic disease.
Latest Developments for Algeta ASA
- United States FDA Approves Algeta ASA's Xofigo
- Algeta ASA Presents Further Sub-Analyses of ALSYMPCA Phase III Study
- Algeta ASA's Radium-223 Dichloride in Cooperation with Bayer Receives Priority Review to the New Drug Application from FDA
- Algeta ASA Announces US Nuclear Regulatory Commission's Licensing Decision for Radium-223 Dichloride
Latest Key Developments in Biotechnology
- Biogen Idec Inc And Swedish Orphan Biovitrum AB Presents New Data From Phase 3 Study Of Long-Lasting Hemophilia Factor Candidate ALPROLIX
- Novation Holdings Inc Announces Acquisition Of Controlling Interest In Solar Energy Initiatives Inc
- La Jolla Pharmaceutical Co Announces FDA Acceptance Of IND For LJPC-501
- Portola Pharmaceuticals Inc Announces Positive Phase 2 Study Results Showing Factor Xa Inhibitor Antidote PRT4445 Reverses Anticoagulant Activity Of Eliquis
- Share this
- Link this
- Digg this
Follow Reuters